CytomX early data point to some safety differentiation, says Jefferies. Jefferies analyst Biren Amin said he thinks some investors may have sought a better efficacy profile from CX-072. However, he notes that the Yervoy combo data provided at ASCO are in the dose-escalation phase and are in heavily pretreated patients, adding that safety seems improved with the CX-072 plus ipi combo. Amin has a Buy rating and $40 price target on CytomX shares, which are down $5.58, or 22%, to $19.96 in afternoon trading
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.